Evidence map›Paper›PMID 42312317›Full record

ArticleEJHaem2026

Mogamulizumab as Bridge to Thiotepa-Based Allogeneic Haematopoietic Stem Cell Transplantation in Sézary Syndrome: A Single-Centre Experience.

Simone Maifredi, Raffaella Sala, Chiara Bottelli, Chiara Pagani, Angela Passi, Rosa Daffini, Alessia Pantaleo, Domenico Russo, Michele Malagola, Marina Venturini and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Simone MaifrediUnit of Blood Diseases and Bone Marrow Transplantation Department of Clinical and Experimental Science University of Brescia ASST Spedali Civili di Brescia Brescia Italy.
Raffaella SalaDepartment of Dermatology University of Brescia ASST Spedali Civili di Brescia Brescia Italy.
Chiara BottelliDepartment of Haematology ASST Spedali Civili di Brescia Brescia Italy.
Chiara PaganiDepartment of Haematology ASST Spedali Civili di Brescia Brescia Italy.
Angela PassiDepartment of Haematology ASST Spedali Civili di Brescia Brescia Italy.
Rosa DaffiniDepartment of Haematology ASST Spedali Civili di Brescia Brescia Italy.
Alessia PantaleoDepartment of Haematology ASST Spedali Civili di Brescia Brescia Italy.
Domenico RussoUnit of Blood Diseases and Bone Marrow Transplantation Department of Clinical and Experimental Science University of Brescia ASST Spedali Civili di Brescia Brescia Italy.
Michele MalagolaUnit of Blood Diseases and Bone Marrow Transplantation Department of Clinical and Experimental Science University of Brescia ASST Spedali Civili di Brescia Brescia Italy.
Marina VenturiniDepartment of Dermatology University of Brescia ASST Spedali Civili di Brescia Brescia Italy.
Daniele AvenosoUnit of Blood Diseases and Bone Marrow Transplantation Department of Clinical and Experimental Science University of Brescia ASST Spedali Civili di Brescia Brescia Italy.
Alessandra TucciDepartment of Haematology ASST Spedali Civili di Brescia Brescia Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sézary syndrome (SS) is an aggressive cutaneous T-cell lymphoma for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only potentially curative treatment. Methods: We report a single-centre series of three consecutive SS patients treated with mogamulizumab as bridging therapy to allo-HSCT using thiotepa-based reduced-intensity conditioning. Results: Mogamulizumab induced rapid clearance of circulating Sézary cells and significant clinical improvement. All patients achieved early and stable full donor chimerism and complete remission. Post-transplant GVHD occurred but was manageable with standard therapy. Conclusion: Early use of mogamulizumab may provide effective disease control and facilitate successful allo-HSCT in SS. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Indexed as

Allo‐HSCTMogamulizumabSézary syndrome

Identifiers

PMID42312317
PMCPMC13270391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.